Rhino Propels Federated AI into the Enterprise Tech Stack Sofwave Medical Reports Second Quarter and First Half 2023 Financial Results and Recent Business Highlights
– Second quarter revenue of $12.4M, +53% year-over-year growth– Second quarter pulse recurring revenue of…
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out…
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out…
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of…
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of…
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1…
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1…
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
– Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blind,…
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
– Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blind,…
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Topline data expected as early as Q1 2024 OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE)…
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Topline data expected as early as Q1 2024 OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE)…
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to…
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to…
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…
Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment…
Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment…
Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo”…